First Manhattan’s BioCryst Pharmaceuticals BCRX Stock Holding History

First Manhattan’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-874,840	Closed	-$6.19M	–	1447
2023 Q3	$6.19M	Hold	874,840	–	–	0.02%	192
2023 Q2	$6.16M	Hold	874,840	–	–	0.02%	188
2023 Q1	$7.3M	Sell	874,840 -993,832	-53%	-$9.57M	0.03%	176
2022 Q4	$21.5M	Buy	1,868,672 +63,600	+4%	+$793K	0.08%	99
2022 Q3	$22.7M	Hold	1,805,072	–	–	0.1%	90
2022 Q2	$19.1M	Buy	+1,805,072	New	+$18.6M	0.08%	108
2015 Q4	–	Sell	-5,000	Closed	-$57K	–	1414
2015 Q3	$57K	Buy	+5,000	New	+$66.7K	﹤0.01%	914

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Manhattan's BCRX Position: Q4 2023 in Review

First Manhattan sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2023, closing a stake of 874,840 shares — an estimated $6.19M sold.

First Manhattan first reported a position in BCRX in Q3 2015 and held it in 7 quarters. The position peaked at $22.7M in Q3 2022. 235 funds tracked by Wall St. Rank hold BCRX as of Q4 2023.

First Manhattan reported no remaining BioCryst Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
First Manhattan sold 874,840 BioCryst Pharmaceuticals shares in Q4 2023, an estimated $6.19M.
First Manhattan first reported a position in BioCryst Pharmaceuticals in Q3 2015 and held it in 7 quarters.
First Manhattan's BioCryst Pharmaceuticals position peaked at $22.7M in Q3 2022.
235 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2023.

Based on First Manhattan's 13F filing for Q4 2023, filed 13 Feb 2024.